M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Vivoryon Therapeutics secures new US patent for varoglutamstat, extending exclusivity to 2044
Clinical stage biotechnology company Vivoryon Therapeutics N.V. (Euronext Amsterdam:VVY) announced on Tuesday that the US Patent and Trademark Office has granted a new composition of matter patent for varoglutamstat, its lead QPCT/L inhibitor.
The patent, issued following an accelerated...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search